A tiny GLP-1 implant is the latest bet to help patients maintain their weight lossVivani Medical is developing an implant of semaglutide, the active ingredient in Novo Nordisk's obesity injection Wegovy and diabetes counterpart Ozempic.{}

Vivani Medical is developing an implant of semaglutide, the active ingredient in Novo Nordisk's obesity injection Wegovy and diabetes counterpart Ozempic.https://www.cnbc.com/2026/07/11/glp-1-implant-from-vivani-medical-aims-to-help-patients-stay-on-treatment.html